Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712944 · ClinicalTrials.gov registry record · Phase 1
Testosterone Replacement in Renal Failure
A Phase 1 study, sponsored by Texas Tech University Health Sciences Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02712944 is a Phase 1 study that was terminated before completion, run by Texas Tech University Health Sciences Center. The registered enrollment target is 21 participants.
The verdict
NCT02712944, a Phase 1 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.
Interventions
- DRUG Saline
- DRUG Testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02712944
The ClinicalTrials.gov registry entry for NCT02712944 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02712944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02712944 about?
NCT02712944 is a clinical study titled "Testosterone Replacement in Renal Failure". The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.
What is the current status of trial NCT02712944?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-07. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02712944?
The interventions under investigation include: Saline (DRUG), Testosterone (DRUG).
Who is sponsoring clinical trial NCT02712944?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.